Skip to main content
KoBioLabs, Inc. logo

KoBioLabs, Inc. — Investor Relations & Filings

Ticker · 348150 ISIN · KR7348150004 KO Manufacturing
Open in API
Filings indexed 174 across all filing types
Latest filing 2024-05-31 Director's Dealing
Country KR South Korea
Listing KO 348150

About KoBioLabs, Inc.

http://kobiolabs.com/en/

KoBioLabs, Inc. is a biotechnology company that develops innovative microbiome-based therapeutics. The company utilizes its proprietary Smartiome® platform, an integrated system for discovering novel drug candidates that employs AI-driven multi-omics analysis and a comprehensive microbiome library with a reverse-translation approach. KoBioLabs is focused on creating a pipeline of new drugs to treat a range of immune, metabolic, and brain disorders. The company also applies advanced technologies, including a microbe-based drug delivery system (mDDS) and biofoundry techniques, to enhance the efficacy of its treatments and address unmet medical needs.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the change in share ownership by a company executive (GwangPyo Ko) of '고바이오랩'. This is a standard regulatory filing for insider transactions/holdings, which falls under the 'Director's Dealing' category.
2024-05-31 Korean
전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (고바이오랩) regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This type of filing details changes to the company's capital structure and debt obligations. Since it involves the redemption/acquisition of debt instruments (convertible bonds), it falls under the 'Capital/Financing Update' category, which covers fundraising and financing activities or changes to capital structure.
2024-05-20 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Kobiolabs' (주식회사 고바이오랩) covering the period from January 1, 2024, to March 31, 2024. It contains detailed business information, financial data, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend status, and board composition. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), which reports the official outcomes of shareholder votes at a general meeting.
2024-03-28 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for the company 'GoBioLab' (주식회사 고바이오랩) for the fiscal year ending December 31, 2023. It includes the independent auditor's report from Samil PricewaterhouseCoopers, detailed financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and extensive notes to the financial statements. This is a formal, full-year financial audit document, not an announcement or a summary, fitting the definition of an Audit Report (AR). FY 2023
2024-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial statements, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. While it contains financial data, it is a standardized regulatory disclosure form used to announce the completion and submission of the audit report to the exchange, rather than the full, multi-page audit report document itself. Therefore, it is classified as a regulatory filing. FY 2023
2024-03-20 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.